ArticleTherapeutic advances in medical oncology2025
Tumor distribution type helps distinguish the prognosis of HCC patients with multiple tumors in BCLC-A stage: a multi-center retrospective study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) patients with multiple tumors have a poor prognosis and need more attention. Objectives: To develop an easily available radiological indicator that can differentiate the prognosis of Barcelona Clinic Liver Cancer stage A (BCLC-A) patients with multiple tumors. Design: This was a retrospective, multicenter study. Magnetic resonance imaging (MRI) data were collected from patients who underwent thermal ablation (TA), laparoscopic hepatectomy (LH), or LH combined with TA at five tertiary hospitals. Methods: Tumor distribution (TD) was classified into three types: same-segment, different-segments, and different-lobes, and three junior doctors (<5 years of experience) were invited to classify the tumors. We compared disease-free survival (DFS) and overall survival (OS) among the different TD types and performed pathological consistency and classification analyses. Six pathological indicators (tumor differentiation, alpha-fetoprotein (AFP), arginase-1 (Arg-1), hepatocyte paraffin 1, cytokeratin-19 (CK-19), and vascular endothelial growth factor (VEGF)) were included. Results: A total of 373 patients were included with a 36.0-month median follow-up. The Fleiss kappa score among the three doctors was 0.803. Patients with the same-segment type had better DFS and OS than those with different-segment ( Conclusion: We established a method based on MRI to accurately differentiate the TD type of multiple tumors for patients in the BCLC-A stage. Patients with concentrated distribution tumors had a better prognosis than patients with dispersed distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.